Among the DUSPs inhibitors that have demonstrated a good antitumour efficacy, BCI, a benzoil-derivative small-molecule inhibitor of DUSP1 and DUSP6, has been reported to reduce BC, MPNST, LUAD, GC and sarcoma growth [28,29,30]. This evidence concerns the gene DUSP6 and breast cancer.